LINDSAY MEADOWS: Open Payments
NPI 1437803343 · AMSTERDAM, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$544 in 25 payments from 12 companies in 2025. Trend: 2023 $396 · 2024 $715 · 2025 $544
Food & beverage: $544
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $97 |
| Novo Nordisk Inc | 4 | $92 |
| PFIZER INC. | 2 | $59 |
| Exeltis, USA Inc. | 3 | $55 |
| Lilly USA, LLC | 2 | $47 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $45 |
| GlaxoSmithKline, LLC. | 2 | $42 |
| Amgen Inc. | 2 | $31 |
| Organogenesis Inc. | 1 | $28 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $17 |
Products named: VRAYLAR, ELIQUIS, SLYND, XIFAXAN, UBRELVY, OTEZLA, Rybelsus, PURAPLY WOUND MATRIX.
Industry payments across NY — which companies pay providers there.
